Gastaldelli, A., Repetto, E., Guja, C., Hardy, E., Han, J., Jabbour, S. A., & Ferrannini, E. (2019). Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes Obes Metab.
Styl ChicagoGastaldelli, Amalia, Enrico Repetto, Cristian Guja, Elise Hardy, Jenny Han, Serge A. Jabbour, a Ele Ferrannini. "Exenatide and Dapagliflozin Combination Improves Markers of Liver Steatosis and Fibrosis in Patients With Type 2 Diabetes." Diabetes Obes Metab 2019.
Citace podle MLAGastaldelli, Amalia, et al. "Exenatide and Dapagliflozin Combination Improves Markers of Liver Steatosis and Fibrosis in Patients With Type 2 Diabetes." Diabetes Obes Metab 2019.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..